

Nicolas Janus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5602351/publications.pdf>

Version: 2024-02-01

35
papers

1,704
citations

430442

18
h-index

276539

41
g-index

53
all docs

53
docs citations

53
times ranked

2204
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management. <i>Cancer</i> , 2007, 110, 1376-1384.	2.0	382
2	Cancer and renal insufficiency results of the BIRMA study. <i>British Journal of Cancer</i> , 2010, 103, 1815-1821.	2.9	160
3	Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Annals of Oncology</i> , 2010, 21, 1395-1403.	0.6	140
4	Renal Safety of Gadolinium-based Contrast Media in Patients with Chronic Renal Insufficiency. <i>Radiology</i> , 2009, 250, 618-628.	3.6	129
5	Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function—the Three-City population-based study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2852-2859.	0.4	84
6	Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study. <i>Liver Transplantation</i> , 2009, 15, 1083-1091.	1.3	76
7	Vaccination and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 800-807.	0.4	71
8	Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANCER and DialYsis) study. <i>Annals of Oncology</i> , 2013, 24, 501-507.	0.6	63
9	Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents. <i>Investigative Radiology</i> , 2014, 49, 109-115.	3.5	61
10	Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients. <i>Cancer</i> , 2014, 120, 2158-2163.	2.0	53
11	Renal insufficiency and cancer treatments. <i>ESMO Open</i> , 2016, 1, e000091.	2.0	52
12	Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 124-133.	2.0	45
13	Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: Results of the FINEST study. <i>European Journal of Radiology</i> , 2010, 73, 357-359.	1.2	45
14	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 745-753.	1.1	41
15	Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues. <i>Lung</i> , 2009, 187, 69-74.	1.4	40
16	Prevalence of renal abnormalities in chronic HBV infection: The HARPE study. <i>Liver International</i> , 2015, 35, 148-155.	1.9	35
17	Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?. <i>AIDS Reviews</i> , 2016, 18, 184-192.	0.5	32
18	Drug Management of Prostate Cancer: Prevalence and Consequences of Renal Insufficiency. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E83-E89.	0.9	23

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3606-3608.	0.4	18
20	Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 492-494.	0.8	18
21	Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study. <i>Transplant International</i> , 2014, 27, 931-938.	0.8	11
22	Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?. <i>Cancers</i> , 2020, 12, 917.	1.7	11
23	Leaning upon international directives for optimization: Anemia—Results of the French Lidoanemia-2 Survey.. <i>Journal of Clinical Oncology</i> , 2015, 33, 180-180.	0.8	9
24	Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. <i>Supportive Care in Cancer</i> , 2022, 30, 2919-2931.	1.0	8
25	Malaria Prophylaxis in Patients with Renal Impairment. <i>Drug Safety</i> , 2013, 36, 83-91.	1.4	7
26	Anticancer Drugs in End-Stage Kidney Disease Patients. <i>Seminars in Dialysis</i> , 2015, 28, 413-416.	0.7	7
27	Results of the MARS study on the management of antiangiogenics—renovascular safety in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5567-5567.	0.8	5
28	Letter. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1340-1341.	1.2	4
29	New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment. <i>Drugs</i> , 2014, 74, 1307-1313.	4.9	4
30	Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 617-623.	1.5	4
31	Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey. <i>Supportive Care in Cancer</i> , 2013, 21, 2743-2748.	1.0	1
32	Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2548-2548.	0.8	1
33	Pulmonary Hypertension: Use of Oral Drugs in Patients with Renal Insufficiency. <i>Clinical Drug Investigation</i> , 2013, 33, 65-69.	1.1	0
34	Course of chronic kidney disease in French patients. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, sfw092.	1.4	0
35	Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France. <i>Supportive Care in Cancer</i> , 2016, 24, 3347-3351.	1.0	0